Paul Molloy has joined MiCardia as CEO, and has been appointed to the company’s board of directors.
Previously, Molloy held senior management positions at Baxter CVG (now Edwards), US Surgical Corporation (now part of Covideon) and Radiance Medical Systems and Endologix. In February 2003, Paul was appointed president and managing director at LMA International, according to the Irvine, Calif.-based company.
MiCardia said it is an emerging company developing Dynaplasty Technology for the percutaneous and non-invasive treatment of structural heart disease including mitral valve regurgitation, tricuspid valve regurgitation and congestive heart failure. Dynaplasty provides devices that can be implanted into the heart and then adjusted either during a procedure or post-operatively.